All In Biotech

Drug Trial Radar · NCT06513806

Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections

Last checked: Nov 20, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

330

Actual

Start

Aug 1, 2024

Primary completion

Sep 25, 2024

Study completion Sep 28, 2024

Sponsor

Lead sponsor
Ain Shams UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections

Conditions

  • Anesthesia; Adverse Effect, Spinal and Epidural

Interventions

  • Granisetron 1 Mg/mL Intravenous SolutionDrug

    will receive granisetron 3 mg iv bolus

  • PethidinDrug

    will receive pethidine 25 mg iv bolus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. treating post spinal shiveringTime frame: perioperatively/periprocedurally

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ain Shams University

    Cairo, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.